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Introduction 
Analgesic and anti-inflammatory drugs are one of the 
most  valuable  medicaments  that  used  in  many  of 
disease  for  relief  of  pain  and  inflammation.  Most 
analgesic and anti-inflammatory drugs available in the 
market,  still  present  a  wide  range  of  many  problems 
such as  efficacy  and  undesired  effects  including  GIT 
disorders and other unwanted effects,
1 that limit their 
clinical usefulness and remain to be solved and leaving 
an  open  door  for  new  and  better  compounds.
2  This 
situation highlights the need for advent of safe, novel 
and  effective  analgesic  and  anti-inflammatory 
compounds.
3 1,2,4-triazole received sheer attention of 
medicinal chemists because of their many therapeutic 
applications  like  anticancer,
4,5  antimicrobial,
6-9 
anticonvulsant,
10  anti-inflammatory,  analgesic,
11 
antidepressant,
12  antitubercular,
13  antimalarial
14  and 
hypoglycemic
15 activities. 
We have reported that 5-methyl-2-[(5-substituted aryl-
4H-1,2,4-triazol-3-yl)methyl]-2,4-dihydro-3H-pyrazol-
3-one  and  5-phenyl-1-[(5-substituted  aryl-4H-1,2,4-
triazol-3-yl)methyl]-1H-tetrazole  had  significant 
anticancer activity specially on renal cancer cell lines 
(UO-31) as well in vitro antibacterial activity against 
gram  positive  bacterial  S.  aureus  NCIM  2079,  B. 
subtillis  NCIM  2063  and  gram  negative  bacterial  E. 
coli NCIM 2065, P. aeruginosa NCIM 2863 strains.
16 
More  recently  we  have  reported  antimicrobial, 
antitubercular  and  anticancer  activity  of  1-[5-
(substituted  aryl)-1,2-oxazol-3-yl]-3,5-diphenyl-1H-
1,2,4-triazole (4a-g).
17 In continuation of our previous 
work
18-20 in this article the attempts have been made to 
explore  the  analgesic  potential  of  some  formerly 
synthesized  1,2,4-triazoles  clubbed  with  pyrazole, 
tetrazole, isoxazole and pyrimidine heterocycles. 
 
Materials and Methods 
The  standard  analgesic  drugs  Ibuprofen  and 
Pentazocine, solvents used for the experimental work 
were commercially procured from E. Merck India and 
Qualigens  India.  Swiss  strain  albino  mice  for  study 
were procured from National Toxicology Center, Pune. 
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Purpose: In the present study in vivo analgesic activity of some previously synthesized 
1,2,4-triazole derivatives containing pyrazole, tetrazole, isoxazole and pyrimidine ring 
have been  evaluated. Methods:  Acetic acid  induced writhing  method and  Hot  plate 
method has been described to study analgesic activity of some 1,2,4-triazole derivatives 
containing pyrazole, tetrazole, isoxazole and pyrimidine as a pharmacological active 
lead.  Results:  Thirty  six  different  derivatives  containing  1,2,4-triazole  ring  were 
subjected to study their in vivo analgesic activity. Chloro, nitro and methoxy, hydroxy 
and  bromo  substituted  derivatives  showed  excellent  analgesic  activity  and 
dimethylamino,  furan  and  phenyl  substituted  derivatives  showed  moderate  analgesic 
activity in both of the methods. Compounds IIIa, IIId, IIIf, IIIi, IIIj, IVa, IVb, IVd, IVf, 
IVh, IVj IV3a and IIj were found to be superior analgesic agents after screening by 
Acetic acid induced writhing method. Compounds IIIb, IIId, IIIf, IIIh, IIIj, IVa, IVb, 
IVd, IVf, IVh, IVi, IV3c, IV3e and IIj were showed analgesic potential after screening 
of Hot plate method. Conclusion: All tested compounds containing 1,2,4-triazole were 
found to be promising analgesic agents, for this activity pyrazole, tetrazole, isoxazole 
and pyrimidine leads might be supported.  
 14    | 
 Khanage et al. 
 Advanced Pharmaceutical Bulletin, 2013, 3(1), 13-18  Copyright © 2013 by Tabriz University of Medical Sciences 
Evaluation of analgesic activity  
Study  protocol  was  approved  by  the  Institutional 
Animal  Ethics  Committee  for  the  purpose  of  control 
and  supervision  of  experiments  on  animals  (IAEC, 
Approval No.1211/ac/08/CPCSEA) before experiment. 
Swiss strain albino mice of either sex weighing 25–30 
g were used for this study. The test compounds were 
administered  intraperitoneally  in  10%  v/v  Tween  80 
suspension.  
 
Acute toxicity study 
The  acute  toxicity  for  the  test  compounds  was 
determined  by  the  Miller  and  Tainter  method 
administering the compounds intraperitoneally. LD50 of 
the  test  compounds  calculated  by  Miller  and  Tainter 
(1944) method,
21 initially least tolerated (smallest) dose 
(100% mortality) and most tolerated (highest) dose (0% 
mortality)  were  determined  by  hit  and  trial  method. 
After determination of two doses we have selected five 
doses in between the least tolerated and most tolerated 
doses were given intraperitoneally to 5 groups of mice, 
10 animals in each group. The animals were observed 
for first 2 hours and then at 6
th and 24
th hour for any 
toxic  symptoms.  After  24  hours,  the  number  of 
deceased  animals  was  counted  in  each  group  and 
percentage of mortality calculated. From the obtained 
data  determined  the  LD50 of  the  test  compounds  by 
using probit value transformations. 
 
Acetic  acid  induced  writhing  method  (Abdominal 
Constriction Test) 
The animals were divided into 38 groups of six mice 
each. The control group of animals was administered 
with  10%  v/v  Tween  80  (0.5  ml)  suspension.  The 
animals  of  another  group  were  injected 
intraperitoneally  with  standard  drug  Ibuprofen  (10 
mg/kg).  After  20  min  of  the  administration  the  test 
compounds, all the groups of mice were given with the 
writhing agent 3% v/v aqueous acetic acid in a dose of 
2  ml/kg  intraperitoneally.  The  writhing  produced  in 
these animals was counted visually for 15 min and the 
numbers of writhings produced in treated groups were 
compared with control group. The results of analgesic 
activity are recorded in Table 1. Analgesic activity in 
percent was calculated by using following formula. 
Protection  =  100-[{(No.  of  writhes  in  treated 
mice)/(No. of writhes in untreated mice)}×100] 
 
Hot plate method  
The method of Eddy and Leimbach was adopted for the 
study. The  temperature  of  a  metal  surface  in  the  hot 
plate test was set at 55±1.0ºC. The time taken by the 
animals to lick the fore or hind paw or jump out of the 
place  was  taken  as  the  reaction  time.  Latency  to  the 
licking  paws  or  jumping  from  plate  was  determined 
before and after treatment. The latency was recorded at 
the time of 0 (just before any treatment) and 15, 30 and 
60  min  after  intraperitoneal  administration  of  test 
compounds. A latency period of 15 sec was defined as 
complete analgesia as cut off time to prevent damage to 
mice.  The  reference  compound  Pentazocine  was 
administered in a dose of 5 mg/kg. The time course of 
hot plate latency was expressed as the percentage of the 
maximum  possible  effect  (%MPE)  according  to  the 
following formula: 
 
%MPE =
(post drug latency) − (pre− drug latency)
(cut − off time) − (pre− drug latency)
× 100 
 
After the treatment  of test  and reference  compounds, 
the pain thresholds of the animals were observed and 
presented in Table 2. 
 
Statistical analysis 
Data  were  presented  as  arithmetic  mean±SEM. 
Statistical analysis was performed by one way variance 
(ANOVA)  followed  by  Dunnett’s  test.  ‘‘p’’  value  of 
less  than  0.05  was  considered  as  statistically 
significant. 
 
Results and Discussion 
Acetic acid induced writhing method  
Abdominal  construction  responses  induced  by  acetic 
acid  is  a  sensitive  procedure  to  establish  efficacy  of 
peripherally acting analgesics, it may causes increase in 
the  level  of  PGE2  and  PGF2a  by  intraperitoneally 
administration  of  acetic  acid.  The  analgesic  activity 
was expressed as percentage of protection. All tested 
compounds exhibited activity in a dose range of 25-100 
mg/kg.  Writhing  episodes  and  percent  protection  of 
tested  compounds  for  analgesic  activity  are 
summarized in Table 1. Compound IIIa, IIId, IIIf, IIIi, 
IIIj, IVa, IVb, IVd, IVf, IVh, IVj IV3a and IIj  (Figure 
1  and  2)  were  found  to  be  superior  analgesic  agents 
with 55, 60, 57, 57, 57, 57, 55, 60, 60, 56, 63, 60 and 
60%  analgesic  activity  respectively  as  compared  to 
other  tested  compounds.  Chloro,  nitro,  methoxy, 
hydroxy  and  bromo  substituted  derivatives  exhibited 
excellent  analgesic  activity  where  as  dimethylamino, 
furan  and  phenyl  substituted  derivatives  showed 
moderate  analgesic  activity.  Substituted  phenyl  ring 
present  on  isoxazole,  pyrimidine  and  1,2,4-triazole 
nucleus  might  have  attributed  crucial  role  to  show 
analgesic  activity.  Compounds  with  substitution  of 
chloro, methoxy, bromo on 4
th position of phenyl ring 
present on isoxazole, pyrimidine and triazole  nucleus 
showed maximum analgesic activity. Compounds IIId, 
IVd, IVf, IVj, IV3a and IIj were exhibited comparative 
analgesic property (up to 60% protection) with standard 
drug Ibuprofen (66%) as illustrated in Table 1. because 
of  4-methoxy,  4-chloro,  2-chloro,  2,4-dimethoxy 
groups  present  on  phenyl  ring  of  pharmacologically 
active  isoxazole,  pyrimidine,  and  triazole  chalcone 
heterocycles.  
 
Hot plate method 
All  compounds  tested  by  Eddy’s  hot  plate  method 
exhibited activity in a dose range of 25-100 mg/kg. The 
analgesic  activity  measured  by  central  analgesia.  
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Pentazocine  5  mg/kg  significantly  increased  the  hot 
plate  latency  producing  a  highest  %MPE  at  69.02. 
Compounds IIIb, IIIj, IVa, IVd, IVf, IVh, IVi, and IIj 
significantly  increased  the  hot  plate  latency  when 
compared  to  the  control  group.  The  highest 
antinociception  induced  by  compounds  IIIj,  IVd  and 
IVf  at  dose  of  50  mg/kg  were  observed  with  64.82, 
66.98  and  67.21  %MPE  respectively.  The  analgesic 
activity  of  compounds  IIIb,  IIId,  IIIf,  IIIh,  IIIj,  IVa, 
IVb,  IVd,  IVf,  IVh,  IVi,  IV3c,  IV3e  and  IIj  were 
comparable to Pentazocine after 15, 30 and 60 min.  2-
chloro,  3-nitro,  4-chloro,  4-methoxy,  4-bromo,  4-
hydroxy  and  2,4-dimethoxy  substituted  analogs 
exhibited dynamic analgesic activity. 4-dimethyl amino 
and 2-furyl substituted compound of tested series of 1-
(3,5-diphenyl-1H-1,2,4-triazol-1-yl)-3-(substituted 
aryl) prop-2-en-1-one (Chalcones) were also acquired 
higher  hot  plate  latency  with  10.76  and  10.74  sec 
respectively after 60 min. Compounds from series of 1-
[5-(substituted aryl)-1,2-oxazol-3-yl]- 3,5-diphenyl-1H-
1,2,4-triazoles and 6-(substituted aryl)-4-(3,5-diphenyl-
1H-1,2,4-triazol-1-yl)-1,6-dihydropyrimidine-2-thiol 
obtained excellent analgesic potential.  
 
 
Figure 1. Structures of compounds of scheme III, IV and IV3. 
 
 
Figure 2. Structures of compounds of scheme I and II. 
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Table 1. Evaluation of analgesic activity by acetic acid induced writhing method. 
Sr. No.  Treatment 
Dose  
mg/kg 
Writhing episodes in 15 min 
(Mean ± S.E.M.) 
Percent 
protection 
1  Control  --  38.70±0.5547  - 
2  Ibuprofen  10  13.19±0.6921**  66 
3  IIIa  50  17.28±0.6647
**  55 
4  IIIb  50  18.24±0.6425
**  53 
5  IIIc  50  24.89±0.5354
**  36 
6  IIId  50  15.65±0.7845
**  60 
7  IIIe  50  26.45±0.8121
**  32 
8  IIIf  50  16.46±0.5744
**  57 
9  IIIg
  50  27.65±0.5478
**  29 
10  IIIh
  50  18.57±0.4545
**  52 
11  IIIi
  50  16.49±0.6545
**  57 
12  IIIj  50  16.47±0.2254
**  57 
13  IVa  50  16.45±0.5456
**  57 
14  IVb  50  17.49±0.5641
**  55 
15  IVc  50  21.73±0.5974
**  44 
16  IVd  50  15.44±0.6133
**  60 
17  IVe  50  22.45±0.5525
**  42 
18  IVf  50  15.36±0.6455
**  60 
19  IVg  50  19.65±0.7322
**  49 
20  IVh
  50  17.22±0.4855
**  56 
21  IVi
  50  19.47±0.6513
**  50 
22  IVj  50  14.24±0.4745
**  63 
23  IV3a  100  15.44±0.4454
**  60 
24  IV3b  100  22.65±0.5546
**  42 
25  IV3c  100  19.47±0.5941
**  50 
26  IV3d  100  21.77±0.4423
**  44 
27  IV3e  100  25.49±0.4473
**  34 
28  IV3f  100  19.42±0.6651
**  50 
29  IV3g  100  26.56±0.4329
**  31 
30  IV3h
  100  28.56±0.7325
**  26 
31  IV3i  100  23.58±0.6423
**  39 
32  IV3j
  100  19.26±0.4523
**  50 
33  Ih  25  20.54±0.6425
**  47 
34  Ii  25  22.89±0.5214
**  41 
35  Ij  25  18.34±0.4527
**  53 
36  IIh
  25  20.57±0.8592
**  47 
37  IIi
  25  22.44±0.6854
**  42 
38  IIj
  25  15.47±0.8957
**  60 
** P < 0.01 represent significant difference when compared with control groups. 
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Table 2. Evaluation of analgesic activity by Hot plate method. 
   
 
Treatment 
Average Reaction 
Time in seconds  
before treatment                             
(Mean ± S.E.M.) 
Reaction time in seconds after treatment 
(Mean ± S.E.M.)   
%MPE 
15 min  30 min  60min 
Control  4.75±0.1547  4.75±0.1583  4.75±0.2563  4.75±0.4941  - 
Pentazocine  4.70±0.4012**  7.70±0.5211**  9.67±0.4302**  11.81±0.3254**  69.02 
IIIa  4.56±0.5221**  7.23±0.6326**  9.23±0.5745**  10.76±0.4369**  59.38 
IIIb  4.63±0.4785**  7.49±0.2234**  9.87±0.3865**  11.15±0.5356**  62.87 
IIIc  4.67±0.4523**  6.52±0.6542**  9.34±0.5413**  9.53±0.4356**  47.04 
IIId  4.63±0.6374**  7.46±0.7585**  9.52±0.2658**  10.47±0.7541**  56.31 
IIIe  4.69±0.4474**  6.45±0.5428**  8.36±0.6756**  9.27 ±0.5854**  44.42 
IIIf  4.65±0.4469**  7.42±0.3769**  9.49±0.5369**  10.71±0.5775**  58.55 
IIIg  4.56±0.5854**  6.70±0.4459**  8.49±0.7474**  9.27±0.6525**  45.11 
IIIh  4.43±0.3544**  7.50±0.7585**  9.57±0.6456**  10.52 ±0.6785**  57.61 
IIIi  4.71±0.4675**  6.39±0.3646**  9.03±0.5236**  9.46±0.5359**  46.16 
IIIj  4.68±0.7548**  7.56±0.5636**  9.52±0.6552**  11.37±0.6426**  64.82 
IVa  4.72±0.5957**  7.68±0.4523**  9.56±0.3356**  11.09±0.5517**  61.96 
IVb  4.67±0.4358**  7.45±0.6984**  9.16±0.3548**  10.59±0.5478**  57.30 
IVc  4.55±0.4785**  6.59±0.4578**  9.44±0.5349**  9.69±0.8689**  49.18 
IVd  4.58±0.5878**  7.66±0.6689**  9.50±0.4245**  11.56±0.6741**  66.98 
IVe  4.39±0.4589**  6.89±0.7481**  8.59±0.6478**  9.75 ±0.4589**  50.51 
IVf  4.66±0.5958**  7.53±0.3549**  9.80±0.3358**  11.61±0.6358**  67.21 
IVg  4.45±0.5869**  7.72±0.5269**  9.58±0.5895**  10.46±0.5692**  56.96 
IVh  4.41±0.5321**  7.80±0.4781**  9.57±0.5696**  10.82 ±0.3324**  60.52 
IVi  4.64±0.2966**  7.56±0.3826**  9.45±0.7851**  10.89±0.5369**  60.32 
IVj  4.52±0.2853**  7.70±0.5239**  9.43±0.4665**  10.44±0.6745 **  56.48 
IV3a  4.64±0.4789**  7.34±0.3545**  9.12±0.3456**  10.12±0.2985**  52.89 
IV3b  4.56±0.5884**  7.11±0.5789**  8.36±0.6398**  9.47±0.6489**  47.03 
IV3c  4.67±0.3956**  7.49±0.5212**  9.27±0.3369**  10.76±0.6245**  58.95 
IV3d  4.73±0.4525**  7.13±0.2845**  9.10±0.3235**  9.46±0.5469**  46.05 
IV3e  4.59±0.5823**  6.93±0.5861**  9.14±0.6478**  10.74 ±0.4369**  59.07 
IV3f  4.54±0.4969**  7.23±0.5326**  9.50±0.3756**  10.32±0.6542**  55.25 
IV3g  4.49±0.5478**  7.02±0.4689**  8.48±0.5225**  8.93±0.5692**  42.24 
IV3h  4.61±0.4526**  6.80±0.4369**  8.55±0.5236**  9.51 ±0.5236**  47.16 
IV3i  4.67±0.6325**  6.56±0.3989**  8.47±0.5364**  9.37±0.6346**  45.49 
IV3j  4.71±0.5963**  7.31±0.2845**  9.46±0.3623**  10.20±0.4126 **  53.35 
Ih  4.46±0.6522**  7.25±0.4545**  8.55±0.2625**  9.88±0.4121**  51.18 
Ii  4.29±0.3532**  7.45±0.4666**  9.12±0.3644**  9.83±0.5481**  51.72 
Ij  4.34±0.5418**  7.75±0.6641**  9.85±0.4236**  10.24±0.3678**  55.34 
IIh  4.54±0.6645**  6.96±0.4425**  8.86±0.3356**  9.87±0.4356**  50.95 
Iii  4.59±0.5414**  6.45±0.3784**  8.22±0.3541**  9.45±0.4678**  46.68 
IIj  4.74±0.4775**  7.35±0.4125**  9.45±0.5925**  10.96±0.6486**  60.62 
Dose: 25 mg/kg  for compounds Ih-Ij, 50mg/kg for IIIa-j and IVa-j, 100mg/kg for IV3a-j and 5mg/Kg for Pentazocine. 
** p<0.01 represent the significant difference when compared control group.   
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Conclusion  
The results of the present investigation reveals that the 
increase  in  analgesic  activity  is  attributed  to  the 
presence of 2-chloro, 3-nitro, 4-chloro, 4-methoxy,  4-
bromo, 4-hydroxy and 2,4-dimethoxy groups on phenyl 
ring  of  isoxazole,  pyrimidine,  pyrazole,  tetrazole  and 
triazole.  All  tested  heterocycles  posses  central  and 
peripheral  analgesic  property.  Perceptibly  the 
comparative  evaluation  of  active  compounds  will 
required in the further studies, the data reported in this 
article may be helpful guide for the medicinal chemist 
who is working in this area. 
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